ABOS
Acumen Pharmaceuticals, Inc. NASDAQ Listed Jul 1, 2021$2.23
Mkt Cap $161.4M
52w Low $1.42
37.4% of range
52w High $3.60
50d MA $2.61
200d MA $2.50
P/E (TTM)
—
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.4x
ROE
-172.3%
P/FCF
-1.2x
RSI (14)
24.20
ATR (14)
$0.21
Beta
0.34
50d MA
$2.61
200d MA
$2.50
Avg Volume
406.3K
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
CIK (SEC)
Phone
434 297 1000
427 Park Street · Newton, VA 22902 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | BMO | -0.36 | -0.45 | -25.2% | 2.43 | +0.4% | +1.6% | +1.6% | +1.6% | +4.7% | -0.4% | — |
| May 12, 2026 | BMO | -0.40 | -0.33 | +18.1% | 2.57 | +0.4% | -3.5% | +0.4% | -4.0% | -4.6% | -4.4% | — |
| Mar 26, 2026 | BMO | -0.50 | -0.41 | +18.0% | 2.55 | -2.7% | -11.4% | -3.1% | +7.8% | +8.1% | +5.9% | — |
| Nov 12, 2025 | BMO | -0.63 | -0.44 | +30.2% | 1.95 | -2.6% | -7.2% | -4.4% | -8.7% | +5.1% | -6.6% | — |
| Aug 12, 2025 | BMO | -0.54 | -0.68 | -25.9% | 1.26 | +0.8% | +0.8% | +10.2% | +1.4% | +0.7% | -3.5% | — |
| May 13, 2025 | BMO | -0.56 | -0.48 | +14.3% | 1.05 | +0.0% | -6.7% | +3.1% | +5.9% | +0.0% | -0.9% | — |
| Mar 27, 2025 | BMO | -0.47 | -0.62 | -31.9% | 1.23 | +0.8% | -3.3% | -7.6% | -1.8% | +0.0% | -8.5% | — |
| Nov 12, 2024 | BMO | -0.36 | -0.50 | -38.9% | 2.68 | +1.9% | -5.6% | +3.2% | -8.0% | -6.7% | +6.7% | — |
| Aug 13, 2024 | BMO | -0.28 | -0.34 | -21.4% | 2.77 | +0.4% | -9.0% | +2.4% | -0.4% | +10.1% | +0.0% | — |
| May 14, 2024 | BMO | -0.23 | -0.25 | -8.7% | 3.69 | +0.0% | +3.0% | -1.8% | -2.1% | +5.2% | -0.8% | — |
| Mar 26, 2024 | BMO | -0.29 | -0.29 | +0.0% | 3.75 | +0.0% | +9.3% | -1.2% | -1.0% | -5.5% | +3.2% | — |
| Nov 13, 2023 | BMO | -0.31 | -0.24 | +22.6% | 2.03 | +3.4% | +4.9% | +11.3% | -5.5% | +1.8% | +3.5% | — |
| Aug 8, 2023 | BMO | -0.36 | -0.28 | +22.2% | 7.00 | +0.0% | -3.1% | +3.8% | +1.4% | +1.1% | -1.4% | — |
| May 9, 2023 | AMC | -0.33 | -0.28 | +15.2% | 5.73 | +0.3% | +15.0% | -13.1% | -2.3% | +10.7% | -9.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $2.63 | $2.56 | -2.7% | -3.0% | -11.4% | -3.1% | +7.8% | +8.1% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $3.27 | $3.50 | +7.0% | +2.1% | -7.5% | -5.5% | +0.0% | -8.6% |
| Jan 27 | BTIG | Maintains | Buy → Buy | — | $2.08 | $2.24 | +7.7% | +30.8% | +3.3% | -0.7% | -6.8% | -0.4% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $1.58 | $1.60 | +1.3% | +5.1% | -6.6% | +0.6% | +0.6% | +8.3% |
| Aug 25 | BofA Securities | Maintains | Buy → Buy | — | $1.53 | $1.52 | -0.7% | -1.3% | -3.3% | -4.8% | -5.8% | +3.8% |
| Mar 28 | UBS | Maintains | Buy → Buy | — | $1.23 | $1.24 | +0.8% | -3.3% | -7.6% | -1.8% | +0.0% | -8.5% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.23 | $1.24 | +0.8% | -3.3% | -7.6% | -1.8% | +0.0% | -8.5% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.73 | +1.9% | -5.6% | +3.2% | -8.0% | -6.7% | +6.7% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.50 | +0.0% | -4.4% | -0.8% | +0.4% | -0.8% | -3.0% |
| Aug 15 | UBS | Maintains | Buy → Buy | — | $2.52 | $2.61 | +3.6% | +2.4% | -0.4% | +10.1% | +0.0% | +0.7% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.77 | $2.78 | +0.4% | -9.0% | +2.4% | -0.4% | +10.1% | +0.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.69 | $3.69 | +0.0% | +3.0% | -1.8% | -2.1% | +5.2% | -0.8% |
| Mar 31 | UBS | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | +9.3% | -1.2% | -1.0% | -5.5% | +3.2% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $7.00 | $7.00 | +0.0% | -3.1% | +3.8% | +1.4% | +1.1% | -1.4% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.00 | $7.00 | +0.0% | -3.1% | +3.8% | +1.4% | +1.1% | -1.4% |
| Jul 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.28 | $11.01 | +75.3% | +54.8% | -17.7% | -7.4% | -1.3% | +1.2% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.28 | $11.01 | +75.3% | +54.8% | -17.7% | -7.4% | -1.3% | +1.2% |
| May 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.45 | $5.69 | +4.4% | +2.6% | +6.6% | -10.9% | -2.1% | +1.0% |
| Mar 28 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.21 | $4.25 | +1.0% | -4.8% | +1.5% | +0.2% | -0.5% | +6.2% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.21 | $4.25 | +1.0% | -4.8% | +1.5% | +0.2% | -0.5% | +6.2% |
| Feb 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $6.50 | -2.3% | -10.7% | -3.2% | +4.0% | -2.0% | +1.5% |
| Nov 15 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.14 | $6.17 | +0.5% | +5.0% | -4.7% | +5.9% | -6.6% | +4.4% |
| Oct 5 | BTIG | Maintains | Buy → Buy | — | $9.55 | $10.32 | +8.1% | +6.5% | -1.0% | -2.5% | -3.8% | -4.8% |
| Jul 15 | BTIG | Maintains | Buy → Buy | — | $6.26 | $6.47 | +3.4% | +0.5% | -6.7% | +3.2% | -4.0% | +5.8% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.92 | +0.8% | -3.7% | +0.2% | +0.8% | +15.8% | +9.1% |
| Mar 29 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.66 | $4.75 | +1.9% | -6.0% | -9.4% | -1.5% | +2.6% | +2.0% |
| Jan 21 | BofA Securities | Upgrade | Neutral → Buy | — | $4.99 | $5.20 | +4.2% | +3.8% | +1.0% | -2.7% | -2.2% | -2.6% |
| Jul 26 | BofA Securities | Maintains | Neutral → Neutral | — | $17.08 | $17.17 | +0.5% | -3.0% | -12.5% | +2.8% | +2.8% | +1.0% |
| Jul 26 | Stifel | Maintains | Buy → Buy | — | $17.08 | $17.17 | +0.5% | -3.0% | -12.5% | +2.8% | +2.8% | +1.0% |
| Jul 26 | UBS | Maintains | Buy → Buy | — | $17.08 | $17.17 | +0.5% | -3.0% | -12.5% | +2.8% | +2.8% | +1.0% |
| Jul 26 | Credit Suisse | Maintains | Outperform → Outperform | — | $17.08 | $17.17 | +0.5% | -3.0% | -12.5% | +2.8% | +2.8% | +1.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Porter DerrellDir | — | Sell | 13,040 | $2.33 | $30K | 35,500 | +0.44% | -4.33% |
| Jun 16, 2026 | Porter DerrellDir | — | Sell | 12,800 | $2.33 | $30K | 35,500 | +0.44% | -4.33% |
| Jun 15, 2026 | Porter DerrellDir | — | Sell | 6,460 | $2.35 | $15K | 48,300 | +0.44% | -4.33% |
| Jun 9, 2026 | Fountain Nathan BDir | — | Sell | 6,400 | $2.23 | $14K | 48,150 | +5.80% | -1.75% |
8-K · 7.01
! Medium
Acumen Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 16
8-K · 2.02
!! High
Acumen Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Aug 12
8-K · 8.01
!! High
Acumen Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Acumen Pharmaceuticals exercised an option to develop two amyloid-beta oligomer-selective antibody candidates using JCR Pharmaceuticals' blood-brain-barrier-penetrating J-Brain Cargo technology, advancing Alzheimer's disease research.
Jun 16
8-K
Acumen Pharmaceuticals, Inc. -- 8-K Filing
Acumen Pharmaceuticals filed an 8-K with the SEC, likely disclosing a material event, though the specific details about whether the company qualifies as an emerging growth company require reviewing the complete filing.
Jun 3
8-K · 2.02
!! High
Acumen Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ABOS disclosed material non-public information under Reg FD, suggesting a significant business development or event occurred that investors need to evaluate for stock impact.
Mar 26
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
ABOS announced an equity issuance, which will dilute existing shareholders' ownership percentages and could pressure the stock price unless proceeds fund significant growth initiatives.
Mar 16
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Sands Capital Alternatives, Llc | 3,720,105 | $9M | Added | Mar 2026 |
| 2 | Blackrock, Inc. | 2,490,115 | $7M | New | Jun 2026 |
| 3 | Alyeska Investment Group, L.p. | 2,454,754 | $6M | Added | Mar 2026 |
| 4 | Franklin Resources Inc | 2,305,096 | $5M | — | Mar 2026 |
| 5 | Adar1 Capital Management, Llc | 2,156,334 | $5M | New | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 1,672,072 | $4M | Added | Jun 2026 |
| 7 | Knollwood Investment Advisory, Llc | 1,628,510 | $4M | — | Mar 2026 |
| 8 | Fmr Llc | 1,157,346 | $3M | Reduced | Mar 2026 |
| 9 | Pathstone Holdings, Llc | 859,110 | $2M | — | Jun 2026 |
| 10 | Laurion Capital Management Lp | 867,046 | $2M | — | Dec 2025 |
| 11 | Renaissance Technologies Llc | 675,025 | $2M | Added | Jun 2026 |
| 12 | Sg Americas Securities, Llc | 719,257 | $2M | Added | Mar 2026 |
| 13 | Two Sigma Investments, Lp | 622,882 | $2M | Added | Jun 2026 |
| 14 | Hudson Bay Capital Management Lp | 725,000 | $2M | — | Dec 2025 |
| 15 | Susquehanna International Group, Llp | 601,476 | $1M | Added | Mar 2026 |
| 16 | Vanguard Portfolio Management Llc | 320,795 | $857K | New | Jun 2026 |
| 17 | Bank Of America Corp /de/ | 320,216 | $756K | Added | Mar 2026 |
| 18 | Morgan Stanley | 333,810 | $704K | Added | Dec 2025 |
| 19 | Marshall Wace, Llp | 192,889 | $455K | Added | Mar 2026 |
| 20 | Acadian Asset Management Llc | 185,850 | $435K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$161.4M
Enterprise Value
$41.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.06x
P/B
1.93x
P/S
—
P/FCF
-1.17x
EV/EBITDA
—
Shares Out
60.6M
Financials (TTM)
Revenue
$0
Net Income
-$105.0M
EBITDA
-$100.4M
Free Cash Flow
-$115.6M
Op Cash Flow
-$115.5M
EPS Basic
$-2.00
EPS Diluted
$-1.64
EPS Forward
$-1.61
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$122.8M
Total Liab.
$52.4M
Total Equity
$70.4M
Cash
$116.9M
LT Debt
$22.4M
Book Value/Sh
$1.16
Debt/Equity
0.44x
Current Ratio
4.07
Quick Ratio
4.07
Returns & Growth
ROE
-172.3%
ROA
-98.8%
ROIC
-121.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
-17.0%
Price Returns
2W
-21.7%
1M
-27.9%
3M
+1.1%
6M
-15.0%
12M
+51.0%
Technicals
52W High
$3.60
52W Low
$1.42
50d MA
$2.61
200d MA
$2.50
RSI (14)
24.20
ATR (14)
$0.21
Beta
0.34
Avg Volume
406K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 24, 2026 10:16am
· Source: financialmodelingprep.com